Location Los Angeles, California, United States Regions Greater Los Angeles Area, West Coast, Western US Gender Male
Website www.remdbio.com/overview/meet-our-team LinkedIn View on LinkedIn
Hai Yan is a reseacher on the discovery and early development of monoclonal antibodies and other protein therapeutics for cell surface receptors implicated in human metabolic diseases. He co-founded REMD Biotherapeutics in 2011 to advance the clinical development of AMG477, in-licensed as REMD-477.
Hai began his biotechnology career at Amgen in
1994 as research scientist in the Metabolic Disorders therapeutic area. He accepted an appointment to Amgen Protein Sciences and developed an innovative monoclonal antibody platform for targeting GPCR signaling and cellular trafficking in 2001.
Hai isolated AMG477, the first therapeutic monoclonal antibody designed to inhibit glucagon receptor signaling and biological for the potential treatment of diabetic patients. He served as AMG477 project leader from its conception to early clinical development.
Hai's success at Amgen was recognized with numerous promotions, including that of scientific director. He graduated with a B.S. in biochemistry, from Nanjing University in China in 1982.
Hai obtained his Ph.D. from Cornell University Medical College in 1991 and performed his postdoctoral research with Joseph Schlessinger at New York University School of Medicine. He is the key inventor and co-inventor for more than a dozen patents.
Hai has authored more than thirty peer-reviewed scientific publications in cell signaling and metabolic disorders.
